Trials / Unknown
UnknownNCT04697446
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
An External Control, Observational, Retrospective Study Assessing the Effect of Pralsetinib Compared With Best Available Therapy for Patients With RET-Fusion Positive Advanced Non-Small Cell Lung Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 279 (estimated)
- Sponsor
- Blueprint Medicines Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an external control, observational, retrospective study designed to compare clinical outcomes for pralsetinib compared with best available therapy for patients with RET-fusion positive advanced NSCLC.
Conditions
- RET-fusion Non Small Cell Lung Cancer
- Lung Neoplasm
- Carcinoma, Non-Small-Cell Lung
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms by Site
- Neoplasms
- Lung Diseases
- Respiratory Tract Diseases
- Carcinoma, Bronchogenic
- Bronchial Diseases
- Head and Neck Neoplasms
- Carcinoma
- Neoplasms by Histologic Type
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Metastatic Non Small Cell Lung Cancer
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2021-10-31
- Completion
- 2021-10-31
- First posted
- 2021-01-06
- Last updated
- 2021-08-10
Locations
3 sites across 3 countries: United States, France, Switzerland
Source: ClinicalTrials.gov record NCT04697446. Inclusion in this directory is not an endorsement.